Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zoledronic Acid Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 10/20 | 0.96 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.93 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 1/20 | 0.93 |
| ▸ | CA2 | P00918 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | MMP2 | P08253 | 1/20 | 0.93 |
| ▸ | MMP9 | P14780 | 1/20 | 0.93 |
| ▸ | MMP8 | P22894 | 1/20 | 0.93 |
| ▸ | MMP14 | P50281 | 1/20 | 0.93 |
| ▸ | CA9 | Q16790 | 1/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zoledronic Acid Anhydrous SCHEMBL3141677 | 1.00 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL515095 | 1.00 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL536817 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3007590 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3154439 | 0.98 | FDPS (0.97) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1586366 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL19054 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL22534391 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160625 | 0.96 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL435847 | 0.96 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117860968-A | Bionic periosteum with bone immunoregulation function and preparation method and application thereof | 中国人民解放军陆军特色医学中心 | 2024-04-12 | — | — | CN | claimed |
| CN-117185281-A | Carbon point capable of quantitatively evaluating bone targeting performance, method for synthesizing carbon point based on chain transfer one-step method, evaluation method and application | 哈尔滨工业大学 | 2023-12-08 | — | — | CN | claimed |
| WO-2023179588-A1 | TRUNCATED VARICELLA-ZOSTER VIRUS ENVELOPE GLYCOPROTEIN GE | 厦门大学 | 2023-09-28 | — | — | WO | claimed |
| CN-115920129-A | Composite microsphere carrying water-soluble medicine and having poly dopamine layer on surface, and preparation method and application thereof | 广东省科学院生物与医学工程研究所 | 2023-04-07 | — | — | CN | claimed |
| CN-115887783-A | Polyester-based composite microsphere with calcium-phosphorus-containing layer on surface as well as preparation method and application of polyester-based composite microsphere | 广东省科学院生物与医学工程研究所 | 2023-04-04 | — | — | CN | claimed |
| CN-115804866-A | Polyester-based microsphere containing drug-loaded calcium inorganic matter and preparation method and application thereof | 广东省科学院生物与医学工程研究所 | 2023-03-17 | — | — | CN | claimed |
| CN-114752560-B | Umbilical cord mesenchymal stem cell culture medium | 苏州科贝生物技术有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114752560-A | Umbilical cord mesenchymal stem cell culture medium | 苏州科贝生物技术有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-110063939-B | Hollow hydroxyapatite drug-loaded particle for shock wave mediated release and preparation method thereof | 邢更彦 | 2021-08-17 | — | — | CN | claimed |
| EP-3246032-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLEDRONIC ACID, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISEASES RELATED TO BONE METABOLISM AND OF TREATMENT-RELATED SIDE EFFECTS SUCH AS HYPOCALCAEMIA | KARL CHRISTOPH (CH) | 2021-08-11 | — | — | EP | claimed |
| EP-2459176-A2 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | claimed |
| CN-102070668-A | Method for preparing zoledronic acid and sodium salt thereof by utilizing phase transfer catalyst | BENGBU BBCA MEDICINE SCIENCE DEV CO LTD | 2011-05-25 | — | — | CN | claimed |
| WO-2011014766-A2 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20110028435-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | claimed |
| EP-1923394-A1 | Reagent and use thereof for the production of bisphosphonates | Sandoz A/S (DK) | 2008-05-21 | — | — | EP | claimed |
| EP-1612212-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | Teva Pharmaceutical Industries Ltd (IL) | 2006-01-04 | — | — | EP | claimed |
| EP-1567533-A2 | ZOLEDRONIC ACID CRYSTAL FORMS, ZOLEDRONATE SODIUM SALT CRYSTAL FORMS, AMORPHOUS ZOLEDRONATE SODIUM SALT, AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-08-31 | — | — | EP | claimed |
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICALS USA, INC. | 2005-03-10 | — | — | US | claimed |
| WO-2005005447-A2 | ZOLEDRONIC ACID CRYSTAL FORMS, ZOLEDRONATE SODIUM SALT CRYSTAL FORMS, AMORPHOUS ZOLEDRONATE SODIUM SALT, AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | SOST, FGF23, PTH1R | FDPS 905/4885GGPS1 588/4885BTN3A1 1364/4885 |
| US-20110028435-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | PYGL, PDE8A, SLC34A1 | FDPS 781/4885GGPS1 1135/4885BTN3A1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.